Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Multiple Sclerosis, Chronic Progressive

Known as: Chronic Progressive Multiple Sclerosis, Multiple Sclerosis, Chronic Progressive [Disease/Finding] 
A form of multiple sclerosis characterized by a progressive deterioration in neurologic function which is in contrast to the more typical relapsing… Expand
National Institutes of Health

Related topics

Related topics

10 relations
In BloodMicrobiologicalchemically inducednursing therapy
Expand

Broader (1)

Multiple Sclerosis

Narrower (3)

Multiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Progressive RelapsingMultiple Sclerosis, Secondary Progressive

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2007
Highly Cited
2007
Exploring recombinant human erythropoietin in chronic progressive multiple sclerosis.
The neurodegenerative aspects of chronic progressive multiple sclerosis (MS) have received increasing attention in recent years… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2004
Highly Cited
2004
Evidence of persistent blood-brain barrier abnormalities in chronic-progressive multiple sclerosis
Brain capillaries were analyzed morphometrically for alterations in organelle distribution and density in biopsy samples of… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 5
Is this relevant?
Highly Cited
2002
Highly Cited
2002
Abnormal endothelial tight junctions in active lesions and normal-appearing white matter in multiple sclerosis.
Blood-brain barrier (BBB) breakdown, demonstrable in vivo by enhanced MRI is characteristic of new and expanding inflammatory… Expand
Is this relevant?
Highly Cited
1999
Highly Cited
1999
Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study.
In experimental animal models of multiple sclerosis demyelinating antibody responses are directed against the myelin… Expand
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
1996
Highly Cited
1996
The treatment of chronic progressive multiple sclerosis with cladribine.
A 2-year, placebo-controlled, double-blind, crossover study was started in 1992 to evaluate cladribine, an immunosuppressive drug… Expand
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Highly Cited
1995
Highly Cited
1995
Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.
A randomized, double-blinded, placebo-controlled, clinical trial of low-dose, weekly, oral methotrexate was performed in 60… Expand
Is this relevant?
Highly Cited
1994
Highly Cited
1994
Cladribine in treatment of chronic progressive multiple sclerosis
Chronic progressive multiple sclerosis (MS) is a severely disabling demyelinating disease in which autoimmune processes seem to… Expand
Is this relevant?
Highly Cited
1993
Highly Cited
1993
Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis.
Magnetic resonance imaging is a highly sensitive method for the detection of the lesions of multiple sclerosis and renders… Expand
Is this relevant?
Highly Cited
1991
Highly Cited
1991
Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis.
BACKGROUND Cachectin, or tumor necrosis factor-alpha (TNF-alpha), is a principal mediator of the inflammatory response and may be… Expand
Is this relevant?
Highly Cited
1984
Highly Cited
1984
Memory disturbance in chronic progressive multiple sclerosis.
Forty-four patients with chronic progressive multiple sclerosis (MS) were compared with age- and education-matched control groups… Expand
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE